Prioritization schema for immunotherapy clinical trials in glioblastoma-Reference-Cited by-同舟云学术

Prioritization schema for immunotherapy clinical trials in glioblastoma

Published:2016-02-18 Issue:6 Volume:5 Page:e1145332
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Hodges Tiffany R.,Ferguson Sherise D.,Caruso Hillary G.,Kohanbash Gary,Zhou Shouhao,Cloughesy Timothy F.,Berger Mitchel S.,Poste George H.,Khasraw Mustafa,Ba Sujuan,Jiang Tao,Mikkelson Tom,Yung W.K. Alfred,de Groot John F.,Fine Howard,Cantley Lewis C.,Mellinghoff Ingo K.,Mitchell Duane A.,Okada Hideho,Heimberger Amy B.

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2016.1145332

Reference227 articles.

1. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

2. GBM AGILE (An Adaptive, Global, Innovative Learning Environment) to Implement Unprecedented International Clinical Trial. National Biomarker Development Alliance 2015; http://nbdabiomarkers.org/gbm-agile

3. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

4. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of novel thyrointegrin αvβ3 antagonist fb-PMT (NP751) in the management of human glioblastoma multiforme;Neuro-Oncology Advances;2022-12-08

2. A novel method of screening combinations of angiostatics identifies bevacizumab and temsirolimus as synergistic inhibitors of glioma-induced angiogenesis;PLOS ONE;2021-06-02

3. An ethics framework for consolidating and prioritizing COVID-19 clinical trials;Clinical Trials;2021-02-02

4. Reprogramming the immunosuppressive microenvironment of IDH1 wild-type glioblastoma by blocking Wnt signaling between microglia and cancer cells;OncoImmunology;2021-01-01

5. Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration;JCI Insight;2020-09-03